Alkem Diabetology (PLS Attempt Quiz Until You Score At Least 90%.)

19 Questions | Total Attempts: 99

SettingsSettingsSettings
Alkem Diabetology (PLS Attempt Quiz Until You Score At Least 90%.) - Quiz

.


Questions and Answers
  • 1. 
    The Inhibitory activity of Evogliptin was___fold more potent than that of Sitagliptin.
    • A. 

      10 Fold

    • B. 

      5 Fold

    • C. 

      100 Fold

    • D. 

      2 Fold

  • 2. 
    Percentage of Evogliptin excreted via urine____%&Through Hepatic route___%.
    • A. 

      50 & 50

    • B. 

      34 & 66

    • C. 

      30 & 70

    • D. 

      40 & 60

  • 3. 
    Half life of Evogliptin______HRS.
    • A. 

      30-50 HRS

    • B. 

      18-24 HRS

    • C. 

      24 HRS

    • D. 

      32-39 HRS

  • 4. 
    Evogliptin is hepatically metabolized and it is neutral to_______enzyme unlike Saxagliptin hence no drug-drug interaction.
    • A. 

      CYP1A2

    • B. 

      CYP3A4

    • C. 

      CYP2C19

    • D. 

      CYPA4

  • 5. 
    What is the IC50 values of Evogliptin Vs Sitagliptin ?
    • A. 

      0.98 nm & 19 nm

    • B. 

      0.98 nm & 16.9 nm

    • C. 

      7.5 nm &19 nm

    • D. 

      None of these

  • 6. 
    M.R.P. of Valera per Tablet ?
    • A. 

      Rs. 23

    • B. 

      Rs. 18.75

    • C. 

      Rs. 19.75

    • D. 

      Rs. 21.85

  • 7. 
    Which option is true among following?
    • A. 

      Evogliptin selectively binds to S1,S2 & S2 extensive sub-units.

    • B. 

      Evogliptin selectively binds to S1,S2 sub-units

    • C. 

      Evogliptin selectively binds to S1,S2,S1' & S2' extensive sub-units.

    • D. 

      Evogliptin selectively binds to S1,S2 & S' sub-units

  • 8. 
    Zilokem CT offers greater BP control vs Olme+HCTZ and the combination lasting for more than 1.3 years.
    • A. 

      True

    • B. 

      False

  • 9. 
    Advantage of SMART Technology
    • A. 

      Maintain 24hrs concentration and reduces toxicity

    • B. 

      Avoid high blood concentration and increased patient compliance

    • C. 

      Both  A & B

    • D. 

      Only A

  • 10. 
    In overweight & obese T2DM with elevated PPG, this indication related which brand ?
    • A. 

      Glucoryl MV 1/2 0.3

    • B. 

      Glucoryl MV 1/2 

    • C. 

      Glucoryl M 1/2/3/4 Forte

    • D. 

      None of these

  • 11. 
    Evogliptin selectively inhibits______enzyme.
    • A. 

      DPP-4

    • B. 

      DPP-8

    • C. 

      DPP-9

    • D. 

      DPP-8 & DPP-9

  • 12. 
    DPP Enzyme stands for
    • A. 

      Di-hydro Peptidyl Peptidase

    • B. 

      Di-Phenyl Peptidase

    • C. 

      Di-Peptidepeptidase

    • D. 

      Di-Peptidyl Peptidase

  • 13. 
    The latest gliptin Evogliptin and Alkem has in licensed this product from the South Korea company called as
    • A. 

      Daewoo Pharma

    • B. 

      Dong Koo

    • C. 

      DONG-A ST

    • D. 

      None of these

  • 14. 
    The selectivity of Evogliptin for DPP-4 enzyme is________
    • A. 

      >3000

    • B. 

      >8000

    • C. 

      >6000

    • D. 

      >10000

  • 15. 
    Valera effectively improved Glycemic control at 24 week and showed similar efficacy to Vildagliptin in 184 indian patients inadequately controlled by metformin. 
    • A. 

      True

    • B. 

      False

  • 16. 
    Evogliptin has mild hypoglycemic events,which were lower than Sitagliptin___Vs___ in a 24 week study.
    • A. 

      0.8% vs 2.5%

    • B. 

      0.9% vs 2.8%

    • C. 

      0.2% vs 2%

    • D. 

      1% vs 2.6%

  • 17. 
    As per the ACC/AHA 2016 guideline in ACS Patients post stent implantation, dual platelet therapy should be given for at least 12 month.
    • A. 

      True

    • B. 

      False

  • 18. 
    Indication of Rosukem CV
    • A. 

      In Dyslipidemia with ASCVD with risk of MI/Stroke/PAD

    • B. 

      In Secondary Prevention

    • C. 

      Both A & B

    • D. 

      None of these

  • 19. 
    Indication of Glucoryl MP 1/2
    • A. 

      In overweight & obese type 2 Diabetics.

    • B. 

      In overweight & obese type 2 Diabetics with elevated FPG & PPG

    • C. 

      In T2DM on dual therapy with uncontrolled FPG & HbA1c

    • D. 

      In Obese Uncontrolled T2DM Patients

Back to Top Back to top